https://www.biopharmawatch.com/news/HSDT/solana-company-reports-q3-2026-results BiopharmaWatch en 2026-11-11T21:25:00.000Z Solana Company Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/GH/guardant-health-offers-convertible-senior-notes BiopharmaWatch en 2026-11-11T21:17:00.000Z Guardant Health Announces Proposed $500.0 Million Offering of Convertible Senior Notes Due 2032 https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-investor-conferences-november-2026 BiopharmaWatch en 2026-11-11T21:15:00.000Z Nektar Therapeutics to Participate in Two Investor Conferences in November https://www.biopharmawatch.com/news/MLSS/milestone-scientific-third-quarter-2026-conference-call BiopharmaWatch en 2026-11-11T21:15:00.000Z Milestone Scientific Schedules Third Quarter 2026 Financial Results Conference Call https://www.biopharmawatch.com/news/ALVO/alvotech-financial-results-september-2026 BiopharmaWatch en 2026-11-11T21:15:00.000Z Alvotech Announces Financial Results for the Nine Months to September 30, 2026, with a Business Update https://www.biopharmawatch.com/news/WGS/genedx-participate-upcoming-investor-conferences-20261111 BiopharmaWatch en 2026-11-11T21:05:00.000Z GeneDx to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/ATEC/atec-announces-participation-upcoming-investor-conferences BiopharmaWatch en 2026-11-11T21:05:00.000Z ATEC Announces Participation in Upcoming Investor Conferences https://www.biopharmawatch.com/news/ACOG/alpha-cognition-reports-q3-2026-results BiopharmaWatch en 2026-11-11T21:05:00.000Z Alpha Cognition Inc. Reports Third Quarter 2026 Financial Results and Provides Operational Update https://www.biopharmawatch.com/news/ONCY/oncolytics-clinical-supply-agreement-pelareorep-loqtorzi BiopharmaWatch en 2026-11-11T21:05:00.000Z Oncolytics Biotech® Announces Clinical Supply Agreement to Evaluate Pelareorep in Combination with LOQTORZI® (toripalimab-tpzi) in Squamous Cell Anal Carcinoma https://www.biopharmawatch.com/news/VANI/vivani-medical-q3-2026-financial-results-update BiopharmaWatch en 2026-11-11T21:05:00.000Z Vivani Medical Reports Third Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/ICU/seastar-medical-q3-2026-financial-results BiopharmaWatch en 2026-11-11T21:05:00.000Z SeaStar Medical Reports Third Quarter 2026 Financial Results and Provides Business Updates https://www.biopharmawatch.com/news/SGP/spyglass-pharma-q3-2026-results-updates BiopharmaWatch en 2026-11-11T21:05:00.000Z SpyGlass Pharma Reports Third Quarter 2026 Financial Results and Provides Corporate Updates https://www.biopharmawatch.com/news/XAIR/beyond-air-financial-results-corporate-update-q3-2026 BiopharmaWatch en 2026-11-11T21:05:00.000Z Beyond Air Reports Financial Results and Provides Corporate Update for the Quarter Ended September 30, 2026 https://www.biopharmawatch.com/news/NSPR/inspiremd-third-quarter-2026-financial-results-timing BiopharmaWatch en 2026-11-11T21:05:00.000Z InspireMD Announces Updated Timing for Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/ENGN/engn-bla-submission-detalimogene-legend-trial-results BiopharmaWatch en 2026-11-11T21:03:00.000Z enGene to Initiate a BLA Submission for Detalimogene by Year End and Reports New Data from LEGEND Trial Pivotal Cohort 1 in BCG-Unresponsive NMIBC https://www.biopharmawatch.com/news/DCTH/delcath-systems-health-uncensored-dr-drew BiopharmaWatch en 2026-11-11T21:01:00.000Z Delcath Systems to Be Featured on “Health Uncensored with Dr. Drew” in Segment Highlighting Advances in Liver-Directed Cancer Treatment https://www.biopharmawatch.com/news/ENGN/engene-appoints-key-executives-regulatory-milestones BiopharmaWatch en 2026-11-11T21:01:00.000Z enGene Appoints Key Executives in Anticipation of Upcoming Regulatory and Commercial Milestones https://www.biopharmawatch.com/news/LKFT/lakefront-biotherapeutics-financial-results-2026 BiopharmaWatch en 2026-11-11T21:01:00.000Z Lakefront Biotherapeutics Reports Nine Months 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/KNSA/kiniksa-pharmaceuticals-jefferies-conference-2026 BiopharmaWatch en 2026-11-11T21:01:00.000Z Kiniksa Pharmaceuticals to Present at Jefferies Global Healthcare Conference in London https://www.biopharmawatch.com/news/MRNA/moderna-mnexspike-effectiveness-older-adults BiopharmaWatch en 2026-11-11T16:10:00.000Z Moderna Announces JAMA Network Open Publication of Real-World Comparative Effectiveness Data for mNEXSPIKE (COVID-19 Vaccine, mRNA) in Adults Aged 65 Years and Older https://www.biopharmawatch.com/news/LLY/new-phase-3b-data-lilly-s-taltz-ixekizumab-zepbound-tirzepatide BiopharmaWatch en 2026-11-11T14:45:00.000Z New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy, patient-reported and metabolic outcomes at one year in adults with psoriatic arthritis and obesity https://www.biopharmawatch.com/news/COSM/cosmos-health-us-ecommerce-update-october-2026 BiopharmaWatch en 2026-11-11T14:30:00.000Z Cosmos Health Provides U.S. E-Commerce Update for October 2026: Monthly Subscription Value Reaches $1.83 Million, Approximately $22 Million Annualized https://www.biopharmawatch.com/news/SINT/sintx-advances-sin-peek-3d-printing-orthopedic-implants BiopharmaWatch en 2026-11-11T14:00:25.000Z SINTX Technologies Advances SiN/PEEK 3D Printing Platform Toward Personalized Orthopedic Implant Commercialization https://www.biopharmawatch.com/news/APVO/aptevo-therapeutics-warrant-exercise-3-million BiopharmaWatch en 2026-11-11T14:00:00.000Z Aptevo Therapeutics Announces Exercise of Existing Warrants for $3.0 Million Gross Proceeds https://www.biopharmawatch.com/news/PMCB/pharmacyte-biotech-reverse-stock-split BiopharmaWatch en 2026-11-11T14:00:00.000Z PharmaCyte Biotech, Inc. Announces Reverse Stock Split https://www.biopharmawatch.com/news/CVS/cvs-health-ai-technology-innovation-awards BiopharmaWatch en 2026-11-11T14:00:00.000Z CVS Health earns global recognition for industry-leading AI and technology innovation https://www.biopharmawatch.com/news/VNDA/nereus-goat-biscayne-bay-miami-art-week BiopharmaWatch en 2026-11-11T14:00:00.000Z NEREUS™ - The Goat of Biscayne Bay Arrives for Miami Art Week https://www.biopharmawatch.com/news/NXGL/nexgel-noteholder-participation-recapitalization-funding BiopharmaWatch en 2026-11-11T14:00:00.000Z NEXGEL Announces Noteholder Participation in Strategic Recapitalization and Approximately $1.2 Million in New Capital Funding https://www.biopharmawatch.com/news/TPST/tempest-therapeutics-licenses-senlang-car-t-platform BiopharmaWatch en 2026-11-11T13:53:00.000Z Tempest Therapeutics Exercises Option to License Senlang’s CD7-Targeted Lentiviral In Vivo CAR-T Platform Following Initial Phase 1 Results with Lead BCMA/GPRC5D Candidate https://www.biopharmawatch.com/news/GH/guardant-health-new-epigenomic-applications BiopharmaWatch en 2026-11-11T13:46:00.000Z Guardant Health Introduces New Epigenomic Applications Providing Deeper Insights for Treatment Selection with Guardant360® Liquid https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-virtual-investor-segment-vatnak-vat-ho BiopharmaWatch en 2026-11-11T13:44:00.000Z Akari Therapeutics Participates in Virtual Investor “What This Means” Segment Featuring Newly Appointed Chief Business Officer Vatnak Vat-Ho https://www.biopharmawatch.com/news/NTHI/neonc-fda-meeting-neon100-accelerated-approval BiopharmaWatch en 2026-11-11T13:37:00.000Z FDA Meeting Could Put NeOnc's NEO100 Experimental Brain Cancer Drug on Faster Track https://www.biopharmawatch.com/news/GMAB/genmab-s-published-articles-association-20261111 BiopharmaWatch en 2026-11-11T13:34:02.000Z Genmab A/S has published its Articles of Association https://www.biopharmawatch.com/news/AGPU/axe-compute-q3-2026-financial-results-call BiopharmaWatch en 2026-11-11T13:30:33.000Z Axe Compute to Host Q3 2026 Financial Results Conference Call https://www.biopharmawatch.com/news/PTIX/protagenic-therapeutics-private-placement-pt00114 BiopharmaWatch en 2026-11-11T13:30:00.000Z Protagenic Therapeutics Announces Private Placement of Up to $5 Million to Advance PT00114 into Its First U.S. Clinical Trial in Generalized Anxiety Disorder https://www.biopharmawatch.com/news/HCA/hca-healthcare-best-employer-veterans BiopharmaWatch en 2026-11-11T13:30:00.000Z HCA Healthcare Named a Best Employer for Veterans by Military Times for Seventh Consecutive Year https://www.biopharmawatch.com/news/IBRX/us-survey-military-veterans-nmibc-barriers-care BiopharmaWatch en 2026-11-11T13:30:00.000Z New U.S. Survey of Military Service Members and Veterans with Non-Muscle Invasive Bladder Cancer Reveals 53% Were Diagnosed at Age 50 or Younger and Barriers to Care https://www.biopharmawatch.com/news/CERS/cerus-corporation-participate-craig-hallum-conference BiopharmaWatch en 2026-11-11T13:30:00.000Z Cerus Corporation to Participate in the 17th Annual Craig-Hallum Alpha Select Conference https://www.biopharmawatch.com/news/CTXR/citius-pharmaceuticals-jefferies-conference-2026 BiopharmaWatch en 2026-11-11T13:30:00.000Z Citius Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in London https://www.biopharmawatch.com/news/PRGO/perrigo-jefferies-miami-consumer-conference BiopharmaWatch en 2026-11-11T13:30:00.000Z Perrigo to Attend the Jefferies Miami Consumer Conference https://www.biopharmawatch.com/news/CAI/caris-launches-study-challenge-testing-myeloid-malignancies BiopharmaWatch en 2026-11-11T13:30:00.000Z Caris Launches Landmark Study to Challenge Fragmented Testing in Myeloid Malignancies https://www.biopharmawatch.com/news/ICCM/icecure-medical-q3-2026-results BiopharmaWatch en 2026-11-11T13:30:00.000Z IceCure Medical to Report Third Quarter 2026 Financial and Operating Results on November 18, 2026 https://www.biopharmawatch.com/news/WVE/wave-life-sciences-jefferies-conference-2026 BiopharmaWatch en 2026-11-11T13:30:00.000Z Wave Life Sciences to Present at Jefferies Global Healthcare Conference in London https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-jefferies-conference-2026 BiopharmaWatch en 2026-11-11T13:30:00.000Z Lexicon Pharmaceuticals to Present at the Jefferies Global Healthcare Conference in London https://www.biopharmawatch.com/news/RARE/ultragenyx-investor-conferences-london-november-2026 BiopharmaWatch en 2026-11-11T13:30:00.000Z Ultragenyx to Participate at Investor Conferences in London https://www.biopharmawatch.com/news/RLYB/rallybio-reverse-stock-split-correction BiopharmaWatch en 2026-11-11T13:15:00.000Z Correction to Press Release Announcing Reverse Stock Split of Rallybio Common Stock in Connection with the Proposed Merger with Avenzo https://www.biopharmawatch.com/news/VBIO/valion-bio-entolimod-national-security-conference BiopharmaWatch en 2026-11-11T13:10:00.000Z Valion Bio Reinforces Commitment to American Troops; Discusses Entolimod with Attendees at RW Baird's National Security Conference https://www.biopharmawatch.com/news/INO/inovio-participate-investor-conferences BiopharmaWatch en 2026-11-11T13:05:00.000Z INOVIO to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/SPAI/safe-pro-awarded-ai-demining-contract-ukraine BiopharmaWatch en 2026-11-11T13:02:16.000Z Safe Pro Awarded Artificial Intelligence Powered Demining Contract by Ukrainian Deminers Association Under United Nations Mine Action Service (UNMAS) Program https://www.biopharmawatch.com/news/NTHI/neonc-fda-meeting-ne100-accelerated-approval BiopharmaWatch en 2026-11-11T13:00:40.000Z NeOnc Technologies Granted FDA Type B End-of-Phase Meeting to Discuss Potential Accelerated Approval Pathway and Phase 3 Confirmatory Trial for Intranasal NEO100 https://www.biopharmawatch.com/news/CLGN/lightsolver-unveil-first-public-demonstration-sc26 BiopharmaWatch en 2026-11-11T13:00:00.000Z LightSolver to Unveil the First Public Demonstration of its All-Optical Computer at SC26 https://www.biopharmawatch.com/news/RXRX/recursion-participate-upcoming-investor-conferences-20261111 BiopharmaWatch en 2026-11-11T13:00:00.000Z Recursion to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/BIAF/bioaffinity-record-testing-volume-october BiopharmaWatch en 2026-11-11T13:00:00.000Z bioAffinity Technologies Reports Record Monthly Testing Volume in October for Its Noninvasive CyPath® Lung Test https://www.biopharmawatch.com/news/TWST/twist-bioscience-inducement-grants-nasdaq BiopharmaWatch en 2026-11-11T13:00:00.000Z Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/TRLV/trulieve-november-2026-event-participation BiopharmaWatch en 2026-11-11T13:00:00.000Z Trulieve Announces November 2026 Event Participation https://www.biopharmawatch.com/news/AMGN/amgen-positive-phase-3-results-dazodalibep-sjogrens-disease BiopharmaWatch en 2026-11-11T13:00:00.000Z AMGEN ANNOUNCES POSITIVE PHASE 3 RESULTS FOR DAZODALIBEP IN SJÖGREN'S DISEASE https://www.biopharmawatch.com/news/ATNM/actinium-radianz-trial-atnm-400-enrollment BiopharmaWatch en 2026-11-11T13:00:00.000Z Actinium Pharmaceuticals Announces Enrollment in the RADIANZ Imaging Clinical Trial Intended to Demonstrate the Pan-Cancer Potential of ATNM-400, A First-in-Class HER3-Targeting Radiotherapy https://www.biopharmawatch.com/news/BIOA/bioage-labs-present-upcoming-investor-conferences BiopharmaWatch en 2026-11-11T13:00:00.000Z BioAge Labs to Present at Upcoming Investor Conferences https://www.biopharmawatch.com/news/FLNA/filana-therapeutics-jill-quigley-board-appointment BiopharmaWatch en 2026-11-11T13:00:00.000Z Filana Therapeutics Names Biopharma Executive Jill M. Quigley to Board https://www.biopharmawatch.com/news/HUMA/humacyte-atev-veithsymposium-2026 BiopharmaWatch en 2026-11-11T13:00:00.000Z Five Presentations, One Leading Innovation: Humacyte’s Acellular Tissue Engineered Vessel Takes Center Stage at VEITH 2026 https://www.biopharmawatch.com/news/ATYR/atyr-pharma-investor-conferences-2026 BiopharmaWatch en 2026-11-11T13:00:00.000Z aTyr Pharma to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/MGX/metagenomi-therapeutics-inc-present-jefferies-global-healthcare-conference-london BiopharmaWatch en 2026-11-11T13:00:00.000Z Metagenomi Therapeutics, Inc. to Present at the Jefferies Global Healthcare Conference in London https://www.biopharmawatch.com/news/TEVA/teva-rd-day-innovative-pipeline-growth BiopharmaWatch en 2026-11-11T12:30:00.000Z Teva Shares Innovative Pipeline Updates and Unveils Path to Future Growth at R&D Day, Targeting $6–7 Billion in Innovative Medicines Revenue by 2030 https://www.biopharmawatch.com/news/FTH/faeth-therapeutics-november-investor-conferences BiopharmaWatch en 2026-11-11T12:30:00.000Z Faeth Therapeutics to Participate in Upcoming November Investor Conferences https://www.biopharmawatch.com/news/ZTS/zoetis-usda-license-cytopoint-plus BiopharmaWatch en 2026-11-11T12:30:00.000Z Zoetis Receives USDA License for Cytopoint Plus™: The First and Only Long-Acting Monoclonal Antibody Providing 75 Days of Allergic Itch Relief in Dogs with Allergic Dermatitis https://www.biopharmawatch.com/news/LYCA/lycia-therapeutics-presentation-jefferies-conference-2026 BiopharmaWatch en 2026-11-11T12:30:00.000Z Lycia Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference https://www.biopharmawatch.com/news/BBIO/bridgebio-acoramidis-data-symposium-2026 BiopharmaWatch en 2026-11-11T12:30:00.000Z BridgeBio to Present New Acoramidis Data on Kidney Function, Real-World Outcomes, and First-Line Treatment Patterns in ATTR-CM at the International Symposium on Amyloidosis 2026 https://www.biopharmawatch.com/news/PYPD/polypid-corporate-update-q3-2026-results BiopharmaWatch en 2026-11-11T12:30:00.000Z PolyPid Provides Corporate Update and Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-investor-conference-november-2026 BiopharmaWatch en 2026-11-11T12:30:00.000Z Dyne Therapeutics to Participate in Upcoming Investor Conference https://www.biopharmawatch.com/news/INKT/mink-therapeutics-q3-2026-results-agent-797 BiopharmaWatch en 2026-11-11T12:30:00.000Z MiNK Therapeutics Reports Third Quarter 2026 Results, First Pre-Commercial Product Revenue from agenT-797, Randomized ARDS Trial Advancing, and ARPA-H Selection for Deployable Cell Therapies https://www.biopharmawatch.com/news/TLRY/breckenridge-distillery-2-mile-high-whiskey-club BiopharmaWatch en 2026-11-11T12:00:33.000Z Whiskey You Won't Find on Shelves: Breckenridge Distillery Launches the 2 Mile High Whiskey Club https://www.biopharmawatch.com/news/ULS/ul-solutions-announces-quarterly-dividend BiopharmaWatch en 2026-11-11T12:00:00.000Z UL Solutions Announces Quarterly Dividend https://www.biopharmawatch.com/news/CSTL/decisiondx-melanoma-data-sdpa-dermato-onco2026 BiopharmaWatch en 2026-11-11T12:00:00.000Z DecisionDx®-Melanoma Data at SDPA and Dermato-Onco2026 Support the Test's Ability to Refine Risk Assessment Beyond AJCC Staging https://www.biopharmawatch.com/news/CDT/cdt-human-skin-studies-vitiligo-tapinarof BiopharmaWatch en 2026-11-11T12:00:00.000Z CDT Commences Human Skin Studies with QIMA Life Sciences on Novel Tapinarof Combinations in Vitiligo https://www.biopharmawatch.com/news/KARD/kardigan-participate-jefferies-global-healthcare-conference BiopharmaWatch en 2026-11-11T12:00:00.000Z Kardigan to Participate in the Jefferies Global Healthcare Conference https://www.biopharmawatch.com/news/INMD/inmode-reports-q3-2026-financial-results BiopharmaWatch en 2026-11-11T12:00:00.000Z InMode Reports Third Quarter 2026 Financial Results: Quarterly GAAP Revenues of $92.1 Million; Reaffirms Full-Year 2026 Financial Outlook https://www.biopharmawatch.com/news/GNPX/genprex-diabetes-gene-therapy-symposium BiopharmaWatch en 2026-11-11T12:00:00.000Z Genprex to Highlight Dual Delivery Strategy for Diabetes Gene Therapy at Future of Cell and Gene Therapy Symposium https://www.biopharmawatch.com/news/ACIU/ac-immune-jefferies-global-healthcare-conference-2026 BiopharmaWatch en 2026-11-11T12:00:00.000Z AC Immune to Present at Jefferies Global Healthcare Conference 2026 https://www.biopharmawatch.com/news/NKTX/nkarta-nkx019-safety-data-acr-convergence-2026 BiopharmaWatch en 2026-11-11T12:00:00.000Z Nkarta Presents Initial Safety Data for NKX019 in 40 Patients Across Five Autoimmune Diseases at ACR Convergence 2026 https://www.biopharmawatch.com/news/COAG/hemab-therapeutics-investor-conferences-2026 BiopharmaWatch en 2026-11-11T12:00:00.000Z Hemab Therapeutics to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-arati-rao-cmo-appointment BiopharmaWatch en 2026-11-11T12:00:00.000Z Nurix Therapeutics Appoints Arati V. Rao, M.D., as Chief Medical Officer https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-preservative-free-ketamine-launch BiopharmaWatch en 2026-11-11T12:00:00.000Z NRx Pharmaceuticals Begins Selling U.S.-Made, Preservative-Free Ketamine Amid Long-Running Shortage https://www.biopharmawatch.com/news/ARVN/arvinas-present-jefferies-global-healthcare-conference BiopharmaWatch en 2026-11-11T12:00:00.000Z Arvinas to Present at Jefferies Global Healthcare Conference https://www.biopharmawatch.com/news/QTTB/q32-bio-2026-jefferies-global-healthcare-conference BiopharmaWatch en 2026-11-11T11:59:00.000Z Q32 Bio to Participate in the 2026 Jefferies Global Healthcare Conference in London https://www.biopharmawatch.com/news/VTRS/viatris-participate-upcoming-investor-conferences-20261111 BiopharmaWatch en 2026-11-11T11:59:00.000Z Viatris to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/TFX/teleflex-present-jefferies-global-healthcare-conference-london BiopharmaWatch en 2026-11-11T11:30:00.000Z Teleflex to Present at the Jefferies Global Healthcare Conference in London https://www.biopharmawatch.com/news/CMPS/compass-pathways-jefferies-global-healthcare-conference BiopharmaWatch en 2026-11-11T11:30:00.000Z Compass Pathways to Participate in Jefferies Global Healthcare Conference on November 18th and 19th https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-jefferies-conference-2026 BiopharmaWatch en 2026-11-11T11:00:00.000Z Amphastar Pharmaceuticals to Present at the Jefferies Global Healthcare Conference in London https://www.biopharmawatch.com/news/NVO/novo-nordisk-200-million-world-diabetes-foundation BiopharmaWatch en 2026-11-11T09:30:00.000Z Novo commits USD 200 million over 10 years to support the World Diabetes Foundation to strengthen diabetes prevention and care https://www.biopharmawatch.com/news/TLX/telix-participate-ubs-global-biopharma-conference BiopharmaWatch en 2026-11-11T07:00:00.000Z Telix to Participate in UBS Global Biopharma Conference https://www.biopharmawatch.com/news/PHAR/pharming-jefferies-global-healthcare-conference-2026 BiopharmaWatch en 2026-11-11T07:00:00.000Z Pharming to participate in fireside chat at Jefferies Global Healthcare Conference in London https://www.biopharmawatch.com/news/IPHA/innate-pharma-event-iph4502-november-2026 BiopharmaWatch en 2026-11-11T06:00:00.000Z Innate Pharma to Host In-Person and Virtual Event on IPH4502 on November 18, 2026 https://www.biopharmawatch.com/news/MRK/pimjetmi-fda-approval-tgct BiopharmaWatch en 2026-11-11T04:05:00.000Z PIMJETMI® (pimicotinib) Developed by Abbisko Therapeutics and Licensed by Merck KGaA, Darmstadt, Germany Receive U.S. FDA Approval for TGCT https://www.biopharmawatch.com/news/STIM/neuronetics-pricing-30-million-offering BiopharmaWatch en 2026-11-11T03:39:00.000Z Neuronetics Announces Pricing of $30 Million Underwritten Public Offering of Common Stock https://www.biopharmawatch.com/news/PRME/prime-medicine-announces-pricing-public-offering-common-stock BiopharmaWatch en 2026-11-11T02:40:00.000Z Prime Medicine Announces Pricing of Public Offering of Common Stock https://www.biopharmawatch.com/news/IBRX/immunitybio-uk-investor-conferences-london-2026 BiopharmaWatch en 2026-11-11T02:31:00.000Z ImmunityBio to Participate in UK Investor Conferences During London Life Sciences Week 2026 https://www.biopharmawatch.com/news/IMMP/immutep-expands-us-patent-estate-efti-therapies BiopharmaWatch en 2026-11-10T23:48:00.000Z Immutep Further Expands United States Patent Estate for Efti-Based Combination Therapies https://www.biopharmawatch.com/news/ENSG/ensign-group-best-nursing-homes-2027 BiopharmaWatch en 2026-11-10T23:40:00.000Z U.S. News & World Report Names Over 100 Independently Operating Ensign Group Affiliates Among Best Nursing Homes for 2027 https://www.biopharmawatch.com/news/IMMP/immutep-ctos-2026-abstract-eftisarc-neo BiopharmaWatch en 2026-11-10T23:02:00.000Z Immutep Announces Release of CTOS 2026 Abstract Reporting First Survival Data from EFTISARC-NEO https://www.biopharmawatch.com/news/GMAB/transactions-shares-linked-securities-genmab-s-made-managerial-employees-their BiopharmaWatch en 2026-11-10T22:57:00.000Z Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons https://www.biopharmawatch.com/news/AVR/anteris-technologies-q3-2026-results BiopharmaWatch en 2026-11-10T22:28:00.000Z Anteris Technologies Announces Results for the Third Quarter of 2026 https://www.biopharmawatch.com/news/RLYB/rallybio-reverse-stock-split-merger-avenzo BiopharmaWatch en 2026-11-10T22:15:00.000Z Rallybio Announces Reverse Stock Split of Common Stock in Connection with the Proposed Merger with Avenzo https://www.biopharmawatch.com/news/SNWV/sanuwave-q3-fy2026-financial-results BiopharmaWatch en 2026-11-10T22:00:00.000Z Sanuwave Announces Q3 FY2026 Financial Results https://www.biopharmawatch.com/news/NVST/envista-prices-430-million-senior-notes BiopharmaWatch en 2026-11-10T21:50:00.000Z Envista Announces Pricing of $430 Million of Senior Notes https://www.biopharmawatch.com/news/EMBC/embecta-report-fiscal-fourth-quarter-2026-results BiopharmaWatch en 2026-11-10T21:40:29.000Z embecta to Report Fiscal Fourth Quarter and Full Year 2026 Financial Results https://www.biopharmawatch.com/news/IBIO/ibio-reports-q1-fiscal-year-2027-results BiopharmaWatch en 2026-11-10T21:30:00.000Z iBio Reports Q1 Fiscal Year 2027 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/ALC/alcon-third-quarter-2026-growth BiopharmaWatch en 2026-11-10T21:30:00.000Z Innovation and Product Launch Momentum Drive Alcon’s Third-Quarter 2026 Growth https://www.biopharmawatch.com/news/PALI/palisade-bio-q3-2026-results-pali-2108-development BiopharmaWatch en 2026-11-10T21:25:00.000Z Palisade Bio Reports Third Quarter 2026 Financial Results and Advances PALI-2108 Phase 2 Clinical Development Programs https://www.biopharmawatch.com/news/PEPG/pepgen-proposed-125-million-public-offering BiopharmaWatch en 2026-11-10T21:23:00.000Z PepGen Announces Proposed $125.0 Million Public Offering of Common Stock https://www.biopharmawatch.com/news/ANAB/anaptys-participation-upcoming-investor-conferences BiopharmaWatch en 2026-11-10T21:20:00.000Z Anaptys Announces Participation in Upcoming Investor Conferences https://www.biopharmawatch.com/news/EPRX/eupraxia-pharmaceuticals-at-the-market-offering BiopharmaWatch en 2026-11-10T21:16:00.000Z Eupraxia Pharmaceuticals Establishes At-The-Market Offering Program https://www.biopharmawatch.com/news/CNTX/context-therapeutics-q3-2026-results-pipeline-progress BiopharmaWatch en 2026-11-10T21:16:00.000Z Context Therapeutics Reports Third Quarter 2026 Financial Results and Pipeline Progress https://www.biopharmawatch.com/news/AYTU/aytu-biopharma-fiscal-2027-q1-results-report BiopharmaWatch en 2026-11-10T21:15:00.000Z Aytu BioPharma to Report Fiscal 2027 First Quarter Operational and Financial Results on November 16, 2026 https://www.biopharmawatch.com/news/BDX/bd-host-investor-day-december-10-2026 BiopharmaWatch en 2026-11-10T21:15:00.000Z BD to Host Investor Day on December 10, 2026 https://www.biopharmawatch.com/news/MDAI/spectral-ai-q3-2026-financial-results BiopharmaWatch en 2026-11-10T21:15:00.000Z Spectral AI Announces 2026 Third Quarter Financial Results https://www.biopharmawatch.com/news/BBOT/bbot-reports-q3-2026-results-and-corporate-update BiopharmaWatch en 2026-11-10T21:15:00.000Z BBOT Reports Third Quarter 2026 Financial Results and Update on Corporate Progress https://www.biopharmawatch.com/news/PRPO/precipio-announces-q3-2026-financial-results BiopharmaWatch en 2026-11-10T21:15:00.000Z Precipio Announces Q3-2026 Financial Results https://www.biopharmawatch.com/news/SNOA/sonoma-pharmaceuticals-q2-2027-financial-results BiopharmaWatch en 2026-11-10T21:10:00.000Z Sonoma Pharmaceuticals Reports Second Fiscal Quarter 2027 Financial Results, Delivering First-ever Net Income Before Income Tax https://www.biopharmawatch.com/news/OBIO/orchestra-biomed-q3-2026-results-business-updates BiopharmaWatch en 2026-11-10T21:10:00.000Z Orchestra BioMed Reports Third Quarter 2026 Financial Results and Highlights Recent Business Updates https://www.biopharmawatch.com/news/LMRI/lumexa-imaging-q3-2026-results BiopharmaWatch en 2026-11-10T21:08:00.000Z Lumexa Imaging Announces Third Quarter 2026 Results https://www.biopharmawatch.com/news/BIIB/biogen-jefferies-global-healthcare-conference BiopharmaWatch en 2026-11-10T21:06:00.000Z Biogen to Participate in the Jefferies Global Healthcare Conference https://www.biopharmawatch.com/news/DGX/quest-diagnostics-declares-quarterly-cash-dividend-20261110 BiopharmaWatch en 2026-11-10T21:06:00.000Z Quest Diagnostics Declares Quarterly Cash Dividend https://www.biopharmawatch.com/news/AUTL/autolus-therapeutics-carlysle-trial-data-acr-2026 BiopharmaWatch en 2026-11-10T21:05:00.000Z Autolus Therapeutics Presents Longer-Term Follow Up Data from CARLYSLE Trial at the American College of Rheumatology Convergence 2026 https://www.biopharmawatch.com/news/DRMA/dermata-therapeutics-corporate-update-q3-2026 BiopharmaWatch en 2026-11-10T21:05:00.000Z Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Third Quarter 2026 https://www.biopharmawatch.com/news/KRMD/koru-medical-systems-q3-2026-results BiopharmaWatch en 2026-11-10T21:05:00.000Z KORU Medical Systems Announces Third Quarter 2026 Results Including Second Consecutive Quarter of Positive Net Income and Adjusted EBITDA https://www.biopharmawatch.com/news/ANRO/alto-neuroscience-q3-2026-results BiopharmaWatch en 2026-11-10T21:05:00.000Z Alto Neuroscience Reports Third Quarter 2026 Financial Results and Recent Business Highlights https://www.biopharmawatch.com/news/ELMD/electromed-inc-growth-fiscal-2027-q1 BiopharmaWatch en 2026-11-10T21:05:00.000Z Electromed, Inc. Delivers Continued Growth in Fiscal 2027 First Quarter https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-q3-2026-results BiopharmaWatch en 2026-11-10T21:05:00.000Z Atara Biotherapeutics Announces Third Quarter 2026 Financial Results and Operational Progress https://www.biopharmawatch.com/news/QTI/qt-imaging-reports-third-quarter-revenue-growth BiopharmaWatch en 2026-11-10T21:05:00.000Z QT Imaging Reports 75% Third Quarter Revenue Growth and Major Medicare Reimbursement Milestone https://www.biopharmawatch.com/news/GH/precision-study-guardant360-guardant-reveal-colorectal-cancer BiopharmaWatch en 2026-11-10T21:05:00.000Z PRECISION Study Published in ESMO Open Highlights Utility of Guardant360® Liquid and Guardant Reveal® to Assess Recurrence Risk After Surgery for Colorectal Cancer Metastases https://www.biopharmawatch.com/news/NUVB/nuvation-bio-jefferies-conference-2026 BiopharmaWatch en 2026-11-10T21:05:00.000Z Nuvation Bio to Present at the Jefferies Global Healthcare Conference in London https://www.biopharmawatch.com/news/INO/inovio-reports-third-quarter-2026-results BiopharmaWatch en 2026-11-10T21:05:00.000Z INOVIO Reports Third Quarter 2026 Financial Results and Recent Business Highlights https://www.biopharmawatch.com/news/SEER/seer-reports-q3-2026-financial-results BiopharmaWatch en 2026-11-10T21:05:00.000Z Seer Reports Third Quarter 2026 Financial Results and Updates Full Year 2026 Revenue Guidance https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-participate-upcoming-investor-conferences BiopharmaWatch en 2026-11-10T21:05:00.000Z Adaptive Biotechnologies to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/GLAS/glass-house-brands-q3-2026-earnings-call BiopharmaWatch en 2026-11-10T21:05:00.000Z Glass House Brands to Host Third Quarter 2026 Earnings Call on November 16, 2026 https://www.biopharmawatch.com/news/FBIO/fortress-biotech-exclusive-license-agreement-fb-607 BiopharmaWatch en 2026-11-10T21:05:00.000Z Fortress Biotech Announces an Exclusive License Agreement for FB-607 for the Treatment of Irritable Bowel Syndrome with Diarrhea (IBS-D) https://www.biopharmawatch.com/news/NXTC/nextcure-business-update-q3-2026 BiopharmaWatch en 2026-11-10T21:05:00.000Z NextCure Provides Business Update and Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/BMEA/biomea-fusion-q3-2026-results BiopharmaWatch en 2026-11-10T21:05:00.000Z Biomea Fusion Reports Third Quarter 2026 Financial Results and Corporate Highlights https://www.biopharmawatch.com/news/PRME/prime-medicine-125-million-public-offering BiopharmaWatch en 2026-11-10T21:05:00.000Z Prime Medicine Announces Proposed $125.0 Million Public Offering of Common Stock https://www.biopharmawatch.com/news/MGX/metagenomi-fda-clearance-mgx-001-trial BiopharmaWatch en 2026-11-10T21:05:00.000Z Metagenomi Therapeutics Announces FDA Clearance of Investigational New Drug Application for MGX-001 and Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/BNGO/bionano-reports-q3-2026-results-business-update BiopharmaWatch en 2026-11-10T21:05:00.000Z Bionano Reports Third Quarter 2026 Results and Provides a Business Update https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-q3-2026-financial-results BiopharmaWatch en 2026-11-10T21:05:00.000Z Capricor Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/PETS/petmeds-announces-q2-financial-results-2026 BiopharmaWatch en 2026-11-10T21:05:00.000Z PetMeds® Announces Second Quarter Financial Results https://www.biopharmawatch.com/news/BRVE/braveheart-bio-q3-2026-financial-results-update BiopharmaWatch en 2026-11-10T21:03:00.000Z Braveheart Bio Reports Third Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/AMRX/amneal-named-biospace-2027-best-place-to-work BiopharmaWatch en 2026-11-10T21:02:00.000Z Amneal Named BioSpace 2027 Best Place to Work, Ranking No.1 Among Large Employers https://www.biopharmawatch.com/news/OMER/omeros-third-quarter-financial-results-november-2026 BiopharmaWatch en 2026-11-10T21:02:00.000Z Omeros Corporation to Announce Third Quarter Financial Results on November 16, 2026 https://www.biopharmawatch.com/news/KURA/kura-oncology-q3-2026-results-update BiopharmaWatch en 2026-11-10T21:02:00.000Z Kura Oncology Reports Third Quarter 2026 Financial Results and Corporate Update https://www.biopharmawatch.com/news/STXS/stereotaxis-q3-2026-financial-results BiopharmaWatch en 2026-11-10T21:02:00.000Z Stereotaxis Reports 2026 Third Quarter Financial Results & Business Updates https://www.biopharmawatch.com/news/GOSS/gossamer-bio-q3-2026-results-business-update BiopharmaWatch en 2026-11-10T21:01:00.000Z Gossamer Bio Announces Third Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-2026-jefferies-conference BiopharmaWatch en 2026-11-10T21:01:00.000Z Neurocrine Biosciences to Present at the 2026 Jefferies Global Healthcare Conference https://www.biopharmawatch.com/news/CARL/carlsmed-reports-q3-2026-results-and-guidance BiopharmaWatch en 2026-11-10T21:01:00.000Z Carlsmed® Reports Third Quarter 2026 Financial Results and Raises Full-Year Guidance https://www.biopharmawatch.com/news/STIM/neuronetics-public-offering-common-stock BiopharmaWatch en 2026-11-10T21:01:00.000Z Neuronetics Announces Proposed Public Offering of Common Stock https://www.biopharmawatch.com/news/EPRX/eupraxia-pharmaceuticals-q3-2026-financial-results BiopharmaWatch en 2026-11-10T21:01:00.000Z Eupraxia Pharmaceuticals Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/STXS/stereotaxis-convertible-note-financing-24-million BiopharmaWatch en 2026-11-10T21:01:00.000Z Stereotaxis Announces Convertible Note Financing of Up To $24 Million https://www.biopharmawatch.com/news/ASND/ascendis-pharma-jefferies-london-healthcare-conference BiopharmaWatch en 2026-11-10T21:01:00.000Z Ascendis Pharma to Participate in the Jefferies London Healthcare Conference https://www.biopharmawatch.com/news/FRNM/freenome-reports-q3-2026-financial-results BiopharmaWatch en 2026-11-10T21:01:00.000Z Freenome Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/IKT/inhibikase-therapeutics-q3-2026-results BiopharmaWatch en 2026-11-10T21:01:00.000Z Inhibikase Therapeutics Announces Third Quarter 2026 Financial Results and Highlights Recent Activity https://www.biopharmawatch.com/news/LKFT/lakefront-presents-2026-jefferies-global-healthcare-conference BiopharmaWatch en 2026-11-10T21:01:00.000Z Lakefront to Present at the 2026 Jefferies Global Healthcare Conference in London https://www.biopharmawatch.com/news/ALGN/align-technology-financial-conference-2023 BiopharmaWatch en 2026-11-10T21:00:00.000Z Align Technology to Speak at Upcoming Financial Conference https://www.biopharmawatch.com/news/ASTH/foothill-regional-medical-center-healthgrades-2027 BiopharmaWatch en 2026-11-10T21:00:00.000Z Foothill Regional Medical Center Recognized Among Healthgrades' 2027 America's 100 Best Hospitals for Orthopedic Surgery and Joint Replacement https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-q3-2026-results-update BiopharmaWatch en 2026-11-10T21:00:00.000Z CUMBERLAND PHARMACEUTICALS REPORTS Q3 2026 FINANCIAL RESULTS & COMPANY UPDATE https://www.biopharmawatch.com/news/TELA/tela-bio-reports-third-quarter-2026-results BiopharmaWatch en 2026-11-10T21:00:00.000Z TELA Bio Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/XCUR/exicure-sells-gpc-100-assets-gpcrt BiopharmaWatch en 2026-11-10T20:50:00.000Z Exicure, Inc. Announces Agreement to Sell GPC-100 Program Assets to GPCRT Inc. for KRW 6.5 Billion https://www.biopharmawatch.com/news/GMAB/capital-increase-genmab-result-employee-warrant-exercise-20261110 BiopharmaWatch en 2026-11-10T20:32:00.000Z Capital Increase in Genmab as a Result of Employee Warrant Exercise https://www.biopharmawatch.com/news/AZN/astrazeneca-grants-healthcare-access-us BiopharmaWatch en 2026-11-10T20:20:00.000Z AstraZeneca awards $1.6 million for programs to improve access to healthcare for patients across the US https://www.biopharmawatch.com/news/MBRX/annamycin-pancreatic-cancer-checkpoint-inhibitors BiopharmaWatch en 2026-11-10T19:45:23.000Z Preclinical Data Show Annamycin Makes Pancreatic Cancer Responsive to Checkpoint Inhibitors, Opening a Combination Path with Immunotherapies https://www.biopharmawatch.com/news/PACS/pacs-top-nursing-homes-2027 BiopharmaWatch en 2026-11-10T19:45:00.000Z Fifty-Eight PACS Post-Acute Locations Named Top Nursing Homes for 2027 by U.S. News & World Report https://www.biopharmawatch.com/news/AMIX/autonomix-medical-us-patent-catheters-sensing-technology BiopharmaWatch en 2026-11-10T19:30:00.000Z Autonomix Medical Granted New U.S. Patent Strengthening Proprietary Catheter-Based Sensing Technology https://www.biopharmawatch.com/news/ROIV/priovant-phase-2-beacon-brepocitinib-results BiopharmaWatch en 2026-11-10T18:24:46.000Z Priovant Announces Publication of Phase 2 BEACON Results for Brepocitinib in Cutaneous Sarcoidosis in JAMA Dermatology https://www.biopharmawatch.com/news/NVS/novartis-ianalumab-sjogrens-disease-acr-2026 BiopharmaWatch en 2026-11-10T17:30:00.000Z Novartis ianalumab two-year data at ACR show further improvements in Sjögren’s disease activity https://www.biopharmawatch.com/news/ADUS/addus-homecare-participate-2026-stephens-conference BiopharmaWatch en 2026-11-10T16:00:00.000Z Addus HomeCare to Participate in 2026 Stephens Annual Investment Conference https://www.biopharmawatch.com/news/HSIC/carequest-henry-schein-bridge-health-network BiopharmaWatch en 2026-11-10T16:00:00.000Z CareQuest and Henry Schein Launch the BRIDGE Health Network to Advance Dental-Medical Integration https://www.biopharmawatch.com/blog/q4-2026-pdufa-dates BiopharmaWatch en 2026-11-10T15:38:57.285Z Q4 2026 PDUFA Dates: 18 FDA Decisions Left https://www.biopharmawatch.com/news/ALNY/alnylam-regeneron-cidebsirna-first-in-human-results BiopharmaWatch en 2026-11-10T15:00:00.000Z Alnylam Collaborator Regeneron Advances CIDEBsiRNA with Promising First-in-Human Results in Patients with MASLD https://www.biopharmawatch.com/news/PFE/pfizer-webcast-jefferies-healthcare-conference-2026 BiopharmaWatch en 2026-11-10T15:00:00.000Z Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference https://www.biopharmawatch.com/news/DCOY/decoy-therapeutics-rd-solution-year-bio-tech-awards BiopharmaWatch en 2026-11-10T14:47:00.000Z Decoy Therapeutics Named “R&D Solution of the Year” in 2026 BioTech Breakthrough Awards https://www.biopharmawatch.com/news/AIM/aim-immunotech-present-webull-corporate-connect-webinar-series BiopharmaWatch en 2026-11-10T14:20:00.000Z AIM ImmunoTech to Present in the Webull Corporate Connect Webinar Series https://www.biopharmawatch.com/news/CVM/cel-sci-dr-eyal-talor-keynote-invitation-multikine-research BiopharmaWatch en 2026-11-10T14:04:00.000Z CEL-SCI’s Dr. Eyal Talor Receives Second International Keynote Invitation on Multikine Head and Neck Cancer Research https://www.biopharmawatch.com/news/ICLR/icon-participate-upcoming-investor-conferences BiopharmaWatch en 2026-11-10T14:00:00.000Z ICON to Participate at Upcoming Investor Conferences https://www.biopharmawatch.com/news/DXCM/dexcom-announces-upcoming-conference-presentation BiopharmaWatch en 2026-11-10T14:00:00.000Z Dexcom Announces Upcoming Conference Presentation https://www.biopharmawatch.com/news/DARE/dare-bioscience-q3-2026-conference-call BiopharmaWatch en 2026-11-10T14:00:00.000Z Daré Bioscience to Host Third Quarter 2026 Financial Results and Company Update Conference Call and Webcast on November 16, 2026 https://www.biopharmawatch.com/news/TXG/breast-cancer-biomarker-study-10x-genomics BiopharmaWatch en 2026-11-10T14:00:00.000Z Shanghai Precision Diagnostics and Fudan University Shanghai Cancer Center Launch Breast Cancer Biomarker Study Using 10x Genomics' Xenium Platform https://www.biopharmawatch.com/news/APT/alpha-pro-tech-q3-2026-financial-results BiopharmaWatch en 2026-11-10T14:00:00.000Z Alpha Pro Tech, Ltd. Announces Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/NNVC/investigational-drug-tackle-measles-outbreaks BiopharmaWatch en 2026-11-10T13:45:00.000Z An Investigational Drug to Tackle Measles Outbreaks https://www.biopharmawatch.com/news/LTRN/lantern-pharma-phase-1a-lp-184-data-publication BiopharmaWatch en 2026-11-10T13:45:00.000Z Lantern Pharma Announces Peer-Reviewed Publication of Phase 1a LP-184 Data in Recurrent Glioblastoma, Supporting a Phase 1b/2a Combination Trial with Spironolactone https://www.biopharmawatch.com/news/SPAI/safe-pro-group-us-army-contract-anduril-ghost-x-drone BiopharmaWatch en 2026-11-10T13:30:11.000Z Safe Pro Group Awarded U.S. Army Prime Contract, Teams with Anduril for Super Intelligence on Ghost-X Drone for Tank Protection https://www.biopharmawatch.com/news/COCH/envoy-medical-regains-nasdaq-compliance BiopharmaWatch en 2026-11-10T13:30:00.000Z Envoy Medical Regains Compliance with Nasdaq Minimum Bid Price Requirement https://www.biopharmawatch.com/news/SUPN/supernus-participate-jefferies-global-healthcare-conference BiopharmaWatch en 2026-11-10T13:30:00.000Z Supernus, Inc. to Participate in the 2026 Jefferies Global Healthcare Conference in London https://www.biopharmawatch.com/news/LITS/lite-strategy-fiscal-2027-q1-results BiopharmaWatch en 2026-11-10T13:30:00.000Z Lite Strategy Reports Fiscal 2027 First Quarter Financial Results https://www.biopharmawatch.com/news/QTI/qt-imaging-gcc-commercial-order-american-hospital-dubai BiopharmaWatch en 2026-11-10T13:30:00.000Z QT Imaging Secures First GCC Commercial Order from American Hospital Dubai, Plans Clinical Research Collaboration https://www.biopharmawatch.com/news/WGS/genedx-research-exome-genome-sequencing BiopharmaWatch en 2026-11-10T13:30:00.000Z GeneDx Research Demonstrates Medical Actionability of Exome and Genome Sequencing Results in Large Real-World Study of More Than 300,000 Patients https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-2026-jefferies-conference BiopharmaWatch en 2026-11-10T13:30:00.000Z CRISPR Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference https://www.biopharmawatch.com/news/CNXU/conexeu-sciences-human-collagen-initiative BiopharmaWatch en 2026-11-10T13:30:00.000Z Conexeu Sciences Launches Human Collagen Initiative for Regenerative Aesthetics as GLP-1 Drives Demand for Tissue Restoration https://www.biopharmawatch.com/news/INBS/intelligent-bio-solutions-record-revenue-fy-2027 BiopharmaWatch en 2026-11-10T13:30:00.000Z Intelligent Bio Solutions Reports Record Fiscal First Quarter 2027 Revenue of $1.39 Million, Marking Sixth Consecutive Quarter of Year-Over-Year Growth https://www.biopharmawatch.com/news/AZTR/azitra-research-bio-europe-atr-cosf-results BiopharmaWatch en 2026-11-10T13:30:00.000Z Azitra, Inc. to Present Research at BIO-Europe® Showing ATR-COSF Reduced Fine Lines and Improved Elasticity in Ex Vivo Human Skin Models https://www.biopharmawatch.com/news/OSTX/os-therapies-uk-mhra-application-herlystic-osteosarcoma BiopharmaWatch en 2026-11-10T13:15:00.000Z OS Therapies Initiates U.K. MHRA Conditional Marketing Authorisation Application for Herlystic (OST-HER2) in the Prevention or Delay of Recurrence in Fully Resected, Pulmonary Metastatic Osteosarcoma https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-q3-2026-results-update BiopharmaWatch en 2026-11-10T13:15:00.000Z Atossa Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Corporate Update https://www.biopharmawatch.com/news/NNOX/nanox-ai-collaboration-dosy-health-thailand BiopharmaWatch en 2026-11-10T13:10:00.000Z Nanox.AI Advances Commercial Collaboration with Dosy Health to Bring AI Cardiac Solution to Thailand https://www.biopharmawatch.com/news/SLDB/solid-biosciences-2026-jefferies-conference BiopharmaWatch en 2026-11-10T13:08:00.000Z Solid Biosciences to Participate in the 2026 Jefferies Global Healthcare Conference https://www.biopharmawatch.com/news/TLSI/trisalus-life-sciences-q3-2026-results BiopharmaWatch en 2026-11-10T13:05:00.000Z TriSalus Life Sciences Reports Third Quarter 2026 Results https://www.biopharmawatch.com/news/RIGL/rigel-present-jefferies-global-healthcare-conference-london BiopharmaWatch en 2026-11-10T13:05:00.000Z Rigel to Present at the Jefferies Global Healthcare Conference in London https://www.biopharmawatch.com/news/VIVS/vivosim-labs-present-safety-data-act-meeting BiopharmaWatch en 2026-11-10T13:05:00.000Z VivoSim Labs to Showcase Multiparametric Human 3D Tissue Safety Data at the American College of Toxicology (ACT) 47th Annual Meeting https://www.biopharmawatch.com/news/ALHC/survey-beverage-swap-healthier-habits-seniors BiopharmaWatch en 2026-11-10T13:00:45.000Z Survey Suggests a Simple Beverage Swap Can Inspire Healthier Habits Among Seniors https://www.biopharmawatch.com/news/NTHI/neonc-ceo-amir-heshmatpour-purchases-shares BiopharmaWatch en 2026-11-10T13:00:40.000Z NeOnc CEO Amir Heshmatpour Adds 80,000 Shares in Open-Market Purchases https://www.biopharmawatch.com/news/ACHV/achieverx-q3-2026-financial-results-business-updates BiopharmaWatch en 2026-11-10T13:00:00.000Z AchieveRx Reports Third Quarter 2026 Financial Results and Provides Business Updates https://www.biopharmawatch.com/news/LLY/life-doesnt-slow-down-foundayo-launch BiopharmaWatch en 2026-11-10T13:00:00.000Z Life doesn't slow down, and Foundayo™ (orforglipron) patient Leanne Morgan is done waiting https://www.biopharmawatch.com/news/LQDA/liquidia-corporation-2026-jefferies-conference BiopharmaWatch en 2026-11-10T13:00:00.000Z Liquidia Corporation to Present at 2026 Jefferies Global Healthcare Conference https://www.biopharmawatch.com/news/COYA/coya-therapeutics-q3-2026-financial-results-update BiopharmaWatch en 2026-11-10T13:00:00.000Z Coya Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Corporate Update https://www.biopharmawatch.com/news/ADGM/adagio-medical-business-update-fulcrum-vt-ide-study BiopharmaWatch en 2026-11-10T13:00:00.000Z Adagio Medical Provides Business Update: 22 Patients Treated with Next-Generation vCLAS™ Ultra System as FULCRUM-VT IDE Sub-Study Advances https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-1000th-srt-system-sale BiopharmaWatch en 2026-11-10T13:00:00.000Z Sensus Healthcare Announces Sale of 1,000th SRT System, Marking Significant Commercial Milestone https://www.biopharmawatch.com/news/AZN/omniose-acquisition-by-astrazeneca BiopharmaWatch en 2026-11-10T13:00:00.000Z Omniose Announces Its Acquisition by AstraZeneca https://www.biopharmawatch.com/news/GEHC/ge-healthcare-establish-magnus-neuro-alliance BiopharmaWatch en 2026-11-10T13:00:00.000Z GE HealthCare announces intent to establish MAGNUS Neuro Alliance to unlock new possibilities in MRI for neuroscience https://www.biopharmawatch.com/news/A/agilent-expands-tumor-profiling-portfolio BiopharmaWatch en 2026-11-10T13:00:00.000Z Agilent Expands Tumor Profiling Portfolio with SureSelect Cancer Research Pan Heme https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-jefferies-conference-2026 BiopharmaWatch en 2026-11-10T13:00:00.000Z Emergent BioSolutions to Participate in Jefferies Global Healthcare Conference https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-appoints-william-ho BiopharmaWatch en 2026-11-10T13:00:00.000Z Spero Therapeutics Appoints William Ho, M.D., Ph.D., to its Board of Directors https://www.biopharmawatch.com/news/WAT/waters-fda-clearance-flow-cytometry-tests BiopharmaWatch en 2026-11-10T13:00:00.000Z Waters Achieves FDA 510(k) Clearance for Ready-to-Use Flow Cytometry Clinical Tests for Leukemia and Lymphoma https://www.biopharmawatch.com/news/XTNT/xtant-medical-q3-2026-results-announcement BiopharmaWatch en 2026-11-10T13:00:00.000Z Xtant Medical to Announce Third Quarter 2026 Financial Results on November 16, 2026 https://www.biopharmawatch.com/news/JNJ/caplyta-lumateperone-bipolar-mania-phase-3-study BiopharmaWatch en 2026-11-10T13:00:00.000Z Johnson & Johnson Announces CAPLYTA (lumateperone) Shows Significant and Rapid Improvement in Bipolar Mania in Second Pivotal Phase 3 Study https://www.biopharmawatch.com/news/LPCN/lipocine-bloom-phase-3-study-lpcn-1154 BiopharmaWatch en 2026-11-10T13:00:00.000Z Lipocine Doses First Participant in BLOOM Phase 3 Study of LPCN 1154 for Postpartum Depression https://www.biopharmawatch.com/news/EOCN/eocene-european-sales-distribution-agreement-cg-100 BiopharmaWatch en 2026-11-10T13:00:00.000Z Eocene Announces its First European Sales and Distribution Agreement to Accelerate the Commercialization of Colospan's CG-100 Device https://www.biopharmawatch.com/news/TRLV/trulieve-expands-medical-cannabis-access-georgia BiopharmaWatch en 2026-11-10T13:00:00.000Z Trulieve Expands Medical Cannabis Access through Riverside Pharmacy in Gainesville, Georgia https://www.biopharmawatch.com/news/CODX/co-diagnostics-reports-third-quarter-2026-results BiopharmaWatch en 2026-11-10T13:00:00.000Z Co-Diagnostics Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/VOR/vor-bio-jefferies-global-healthcare-conference-2026 BiopharmaWatch en 2026-11-10T13:00:00.000Z Vor Bio To Participate in 2026 Jefferies Global Healthcare Conference https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-jefferies-conference-2026 BiopharmaWatch en 2026-11-10T13:00:00.000Z Intellia Therapeutics to Present at Jefferies Global Healthcare Conference in London https://www.biopharmawatch.com/news/ALXO/alx-oncology-investor-conferences-2026 BiopharmaWatch en 2026-11-10T13:00:00.000Z ALX Oncology to Present at Upcoming Investor Conferences https://www.biopharmawatch.com/news/ODTX/odyssey-therapeutics-tnfr2-agonism-potential BiopharmaWatch en 2026-11-10T13:00:00.000Z Odyssey Therapeutics Announces Publication Highlighting Differentiated Therapeutic Potential of TNFR2 Agonism https://www.biopharmawatch.com/news/PMVP/pmv-pharma-third-quarter-2026-results BiopharmaWatch en 2026-11-10T13:00:00.000Z PMV Pharmaceuticals Reports Third Quarter 2026 Financial Results and Corporate Highlights https://www.biopharmawatch.com/news/PDSB/pds-biotech-warrants-exercise-nantworks-3-9-million BiopharmaWatch en 2026-11-10T13:00:00.000Z PDS Biotech Announces Exercise of Warrants by NantWorks for Approximately $3.9 Million in Gross Proceeds https://www.biopharmawatch.com/news/NSRX/nasus-pharma-abstracts-acaa-2026 BiopharmaWatch en 2026-11-10T13:00:00.000Z Nasus Pharma Announces Abstracts Accepted for Presentation at ACAAI 2026 https://www.biopharmawatch.com/news/BIVI/biovie-bezisterim-parkinsons-adpd2027 BiopharmaWatch en 2026-11-10T13:00:00.000Z BioVie Invited to Present Data on Bezisterim in Parkinson’s Disease at the AD/PD2027 International Conference on Alzheimer's & Parkinson’s Diseases https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-participate-jefferies-global-healthcare-conference-london BiopharmaWatch en 2026-11-10T13:00:00.000Z Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in London https://www.biopharmawatch.com/news/KRYS/krystal-biotech-investor-conferences-2026 BiopharmaWatch en 2026-11-10T13:00:00.000Z Krystal Biotech to Present at Upcoming Investor Conferences https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-q3-2026-results-update BiopharmaWatch en 2026-11-10T13:00:00.000Z Corbus Pharmaceuticals Reports Q3 2026 Financial Results and Provides a Corporate Update https://www.biopharmawatch.com/news/CING/cingulate-ct-1301-update-interview BiopharmaWatch en 2026-11-10T13:00:00.000Z Shane Schaffer, Cingulate Chairman and CEO, Provides Update on CTx-1301 in Interview with Innovators with Jane King https://www.biopharmawatch.com/news/MNKD/mannkind-participate-upcoming-investor-conferences BiopharmaWatch en 2026-11-10T13:00:00.000Z MannKind to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-investor-conferences-nov-dec-2026 BiopharmaWatch en 2026-11-10T13:00:00.000Z Spyre Therapeutics to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/NVS/novartis-access-to-medicine-index-2026 BiopharmaWatch en 2026-11-10T13:00:00.000Z Novartis ranks first place in 2026 Access to Medicine Index https://www.biopharmawatch.com/news/TYRA/tyra-biosciences-q3-2026-results BiopharmaWatch en 2026-11-10T13:00:00.000Z Tyra Biosciences Reports Third Quarter 2026 Financial Results and Recent Highlights https://www.biopharmawatch.com/news/MRK/philip-seo-editor-in-chief-merck-manuals BiopharmaWatch en 2026-11-10T13:00:00.000Z Philip Seo, MD, Named Editor-in-Chief of The Merck Manuals https://www.biopharmawatch.com/news/CSBR/champions-oncology-contract-research-award BiopharmaWatch en 2026-11-10T12:59:59.000Z BioTech Breakthrough Acknowledges Champions Oncology Innovation with the “Contract Research and Development Innovation Award” https://www.biopharmawatch.com/news/CMND/clearmind-medicine-psychedelic-summit-invitation BiopharmaWatch en 2026-11-10T12:32:00.000Z Clearmind Medicine Among Top Biopharma Companies Invited to join Washington DC, Psychedelic Summit https://www.biopharmawatch.com/news/KLRS/kalaris-reports-q3-2026-financial-results BiopharmaWatch en 2026-11-10T12:30:30.000Z Kalaris Reports Third Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/DYAI/dyadic-brig-strive-collaboration-alpha-lactalbumin BiopharmaWatch en 2026-11-10T12:30:13.000Z Dyadic Applied BioSolutions, BRIG BIO and Strive Nutrition Announce a Strategic Collaboration to Accelerate the Commercialization of Precision-Fermented Alpha-Lactalbumin for Premium Nutrition Markets in the U.S. https://www.biopharmawatch.com/news/QUCY/quantum-cyber-expands-exclusive-license-unmanned-warfare BiopharmaWatch en 2026-11-10T12:30:00.000Z Quantum Cyber Expands and Secures Exclusive Quantum Photonic Array License, Extending Its Quantum Layer Across Air, Surface and Subsea Unmanned Warfare Domains https://www.biopharmawatch.com/news/ZTS/zoetis-participate-jefferies-global-healthcare-conference BiopharmaWatch en 2026-11-10T12:30:00.000Z Zoetis to Participate in the Jefferies Global Healthcare Conference in London https://www.biopharmawatch.com/news/MANE/veradermics-q3-2026-financial-results BiopharmaWatch en 2026-11-10T12:30:00.000Z Veradermics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress https://www.biopharmawatch.com/news/MIRM/mirum-pharmaceuticals-azure-4-phase-3-study-results BiopharmaWatch en 2026-11-10T12:30:00.000Z Mirum Pharmaceuticals Announces Primary Endpoint Met in AZURE-4 Phase 3 Study and Highlights Long-Term Brelovitug Data Presented at AASLD https://www.biopharmawatch.com/news/ABUS/arbutus-reports-q3-2026-results-update BiopharmaWatch en 2026-11-10T12:30:00.000Z Arbutus Reports Third Quarter 2026 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/CNSY/cerenome-appoints-ron-andrews-chief-business-officer BiopharmaWatch en 2026-11-10T12:30:00.000Z Cerenome Appoints Director Ron Andrews as Chief Business Officer https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-investor-conferences-november-2026 BiopharmaWatch en 2026-11-10T12:30:00.000Z Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences https://www.biopharmawatch.com/news/XLO/xilio-therapeutics-q3-2026-financial-results BiopharmaWatch en 2026-11-10T12:30:00.000Z Xilio Therapeutics Reports Third Quarter 2026 Financial Results and Provides Pipeline and Business Updates https://www.biopharmawatch.com/news/XGN/exagen-inc-reports-q3-2026-financial-results BiopharmaWatch en 2026-11-10T12:30:00.000Z Exagen Inc. Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/BWAY/brainsway-q3-2026-financial-results BiopharmaWatch en 2026-11-10T12:30:00.000Z BrainsWay Reports Third Quarter 2026 Financial Results and Operational Highlights https://www.biopharmawatch.com/news/ARDX/ardelyx-jefferies-global-healthcare-conference-2026 BiopharmaWatch en 2026-11-10T12:30:00.000Z Ardelyx to Participate at the Jefferies Global Healthcare Conference in London https://www.biopharmawatch.com/news/BKD/brookdale-resident-alzheimers-journey-grey-take BiopharmaWatch en 2026-11-10T12:17:00.000Z Brookdale Resident Shares Her Alzheimer's Journey on The Grey Take https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-q3-2026-results BiopharmaWatch en 2026-11-10T12:15:00.000Z Cellectar Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate Updates https://www.biopharmawatch.com/news/IONS/ionis-present-upcoming-investor-conferences BiopharmaWatch en 2026-11-10T12:05:00.000Z Ionis to present at upcoming investor conferences https://www.biopharmawatch.com/news/PEPG/pepgen-reports-third-quarter-2026-results BiopharmaWatch en 2026-11-10T12:05:00.000Z PepGen Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights https://www.biopharmawatch.com/news/OSCR/oscar-expands-health-plans-ohio-2027 BiopharmaWatch en 2026-11-10T12:01:00.000Z Oscar Grows Across Ohio to Serve Nearly the Entire State for 2027 Open Enrollment https://www.biopharmawatch.com/news/PEPG/pepgen-positive-phase-2-freedom2-dm1-results BiopharmaWatch en 2026-11-10T12:01:00.000Z PepGen Announces Positive Phase 2 FREEDOM2-DM1 10 mg/kg Results Demonstrating Highest Reported Splicing Correction and Improvements Across Multiple Functional Measures https://www.biopharmawatch.com/news/BEAM/beam-therapeutics-beacon-trial-sickle-cell BiopharmaWatch en 2026-11-10T12:00:50.000Z Beam Therapeutics Announces Positive Topline Pivotal Data from BEACON Phase 1/2 Trial of Risto-cel in Patients with Sickle Cell Disease https://www.biopharmawatch.com/news/UPB/upstream-bio-q3-2026-results-phase-3-trials-planned BiopharmaWatch en 2026-11-10T12:00:40.000Z Upstream Bio Reports Third Quarter 2026 Financial Results and Highlights Continued Progress https://www.biopharmawatch.com/news/AUTL/autolus-therapeutics-q3-2026-results BiopharmaWatch en 2026-11-10T12:00:00.000Z Autolus Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates https://www.biopharmawatch.com/news/FATE/fate-therapeutics-ft819-acr-convergence-2026 BiopharmaWatch en 2026-11-10T12:00:00.000Z Fate Therapeutics Presents New FT819 Data at ACR Convergence 2026 Highlighting Meaningful Clinical Responses in Lupus Without the Use of Conditioning Chemotherapy https://www.biopharmawatch.com/news/MRNA/moderna-presents-at-jefferies-conference-november-2026 BiopharmaWatch en 2026-11-10T12:00:00.000Z Moderna to Present at Upcoming Conference in November 2026 https://www.biopharmawatch.com/news/SRRK/scholar-rock-q3-2026-results BiopharmaWatch en 2026-11-10T12:00:00.000Z Scholar Rock Reports Third Quarter 2026 Financial Results and Recent Business Highlights https://www.biopharmawatch.com/news/MASS/908-devices-q3-2026-results-record-revenue BiopharmaWatch en 2026-11-10T12:00:00.000Z 908 Devices Reports Third Quarter 2026 Financial Results and Achieves Record Revenue https://www.biopharmawatch.com/news/CGEN/compugen-unigenx-platform-pegs-europe-summit BiopharmaWatch en 2026-11-10T12:00:00.000Z Compugen to Present UnigenX™ Platform at the 18th Annual PEGS Europe Summit https://www.biopharmawatch.com/news/BMEA/biomea-fusion-phase-1-results-bmf-650-obesityweek-2026 BiopharmaWatch en 2026-11-10T12:00:00.000Z Biomea Fusion Announces Poster Presentation of Phase 1 Results for BMF-650, its Investigational Next-Generation Oral Small Molecule GLP-1 Receptor Agonist, at ObesityWeek® 2026 https://www.biopharmawatch.com/news/COAG/hemab-therapeutics-q3-2026-update BiopharmaWatch en 2026-11-10T12:00:00.000Z Hemab Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/CGEM/cullinan-therapeutics-update-q3-2026-results BiopharmaWatch en 2026-11-10T12:00:00.000Z Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-investor-conferences-2026 BiopharmaWatch en 2026-11-10T12:00:00.000Z Nurix Therapeutics to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/HUMA/humacyte-reports-q3-2026-results-symvess-revenue-growth BiopharmaWatch en 2026-11-10T12:00:00.000Z Humacyte Reports Third Quarter 2026 Results, Highlighted by More Than Doubling Symvess Revenue and Expanding Commercial Adoption https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-q3-2026-results BiopharmaWatch en 2026-11-10T12:00:00.000Z Harvard Bioscience Announces Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/KLRA/kailera-therapeutics-obesityweek-2026 BiopharmaWatch en 2026-11-10T12:00:00.000Z Kailera Therapeutics to Present at ObesityWeek 2026 https://www.biopharmawatch.com/news/LEGN/legend-biotech-q3-2026-results-highlights BiopharmaWatch en 2026-11-10T12:00:00.000Z Legend Biotech Reports Third Quarter 2026 Results and Recent Highlights https://www.biopharmawatch.com/news/CTY/city-therapeutics-phase-1-trial-city-rbp4-stargardt-disease BiopharmaWatch en 2026-11-10T12:00:00.000Z City Therapeutics Announces First Participant Dosed in Phase 1 Clinical Trial of CITY-RBP4 for the Treatment of Stargardt Disease https://www.biopharmawatch.com/news/LNSR/lensar-reports-q3-2026-financial-results BiopharmaWatch en 2026-11-10T12:00:00.000Z LENSAR® Reports Third Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/GANX/gain-therapeutics-q3-2026-results-update BiopharmaWatch en 2026-11-10T12:00:00.000Z Gain Therapeutics Reports Financial Results for Third Quarter 2026 and Provides Corporate Update https://www.biopharmawatch.com/news/OCGN/ocugen-celairis-exclusive-license-agreement-ocu400 BiopharmaWatch en 2026-11-10T12:00:00.000Z Ocugen and Celairis Therapeutics Enter into Exclusive License Agreement for OCU400 in Australia, New Zealand, and ASEAN https://www.biopharmawatch.com/news/CALC/calcimedica-q3-2026-financial-results-clinical-updates BiopharmaWatch en 2026-11-10T12:00:00.000Z CalciMedica Reports Third Quarter 2026 Financial Results and Provides Clinical & Corporate Updates https://www.biopharmawatch.com/news/SION/sionna-therapeutics-q3-2026-financial-results BiopharmaWatch en 2026-11-10T12:00:00.000Z Sionna Therapeutics Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/OLMA/olema-oncology-reports-q3-2026-results BiopharmaWatch en 2026-11-10T12:00:00.000Z Olema Oncology Reports Third Quarter 2026 Financial and Operating Results https://www.biopharmawatch.com/news/IMTX/immatics-q3-2026-financial-results-business-update BiopharmaWatch en 2026-11-10T12:00:00.000Z Immatics Announces Third Quarter 2026 Financial Results and Business Update https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-business-updates-q3-2026-results BiopharmaWatch en 2026-11-10T12:00:00.000Z Ovid Therapeutics Reports Business Updates and Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/NTRA/natera-incyte-phase-ii-study-colorectal-cancer BiopharmaWatch en 2026-11-10T12:00:00.000Z Natera Announces Clinical Collaboration with Incyte on Interventional Phase II Study in Colorectal Cancer https://www.biopharmawatch.com/news/IRD/opus-genetics-q3-2026-financial-results-update BiopharmaWatch en 2026-11-10T12:00:00.000Z Opus Genetics Announces Financial Results for Third Quarter 2026 and Provides Corporate Update https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-q3-2026-results BiopharmaWatch en 2026-11-10T11:45:00.000Z Protalix BioTherapeutics Reports Third Quarter 2026 Financial and Business Results https://www.biopharmawatch.com/news/PGEN/precigen-q3-results-papzimeos-revenue-growth BiopharmaWatch en 2026-11-10T11:30:00.000Z Precigen Posts Strong Q3: PAPZIMEOS Net Revenue Rose 37%; Positive Cash Flow Achieved Ahead of Schedule https://www.biopharmawatch.com/news/LQDA/liquidia-corporation-third-quarter-2026-results BiopharmaWatch en 2026-11-10T11:30:00.000Z Liquidia Corporation Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/ZEPP/zepp-health-third-quarter-2026-results BiopharmaWatch en 2026-11-10T11:30:00.000Z Zepp Health Corporation to Report Third Quarter 2026 Financial Results on November 22, 2026 https://www.biopharmawatch.com/news/BDTX/black-diamond-therapeutics-silevertinib-phase-2-results BiopharmaWatch en 2026-11-10T11:30:00.000Z Black Diamond Therapeutics Announces Positive Updated Silevertinib Phase 2 Results, FDA Feedback Supporting a Clear Path to Potential Registration in 1L EGFR-NCM NSCLC, and Provides Corporate Update https://www.biopharmawatch.com/news/MXCT/maxcyte-q3-2026-financial-results-guidance-update BiopharmaWatch en 2026-11-10T11:01:00.000Z MaxCyte Reports Third Quarter 2026 Financial Results and Updates Full Year 2026 Total Revenue Guidance https://www.biopharmawatch.com/news/MXCT/maxcyte-acquire-akron-bio-cell-therapy-manufacturing BiopharmaWatch en 2026-11-10T11:00:00.000Z MaxCyte to Acquire Akron Bio, Expanding its Offerings Across Cell Therapy Manufacturing and Expecting to Nearly Double Revenue Base https://www.biopharmawatch.com/news/IMRN/immuron-engages-lifescapital-strategic-initiatives BiopharmaWatch en 2026-11-10T11:00:00.000Z Immuron Engages LifeSci Capital as its Exclusive Financial Advisor to Explore Strategic Initiatives https://www.biopharmawatch.com/news/VCRE/vicore-pharma-jefferies-conference-2026 BiopharmaWatch en 2026-11-10T07:15:00.000Z Vicore Pharma to Participate in the Jefferies Global Healthcare Conference https://www.biopharmawatch.com/news/VALN/valneva-chikungunya-vaccine-ixchiq-five-year-data BiopharmaWatch en 2026-11-10T06:00:00.000Z Valneva Reports Sustained 94% Seroresponse Five Years After a Single Dose of Chikungunya Vaccine IXCHIQ® https://www.biopharmawatch.com/news/PODD/insulet-launches-gluconaut-comic-marvel BiopharmaWatch en 2026-11-10T05:00:00.000Z Insulet Introduces a New Hero, Powered by Omnipod®, to Inspire and Empower the Diabetes Community Through Representation, in Collaboration with Marvel Comics https://www.biopharmawatch.com/news/ACAD/acadia-pharmaceuticals-nuplazid-patent-appeal BiopharmaWatch en 2026-11-10T04:47:00.000Z Acadia Pharmaceuticals Comments on Federal Circuit Oral Argument in NUPLAZID® Formulation Patent Appeal https://www.biopharmawatch.com/news/CYPH/cypherpunk-technologies-q3-2026-results BiopharmaWatch en 2026-11-10T00:00:00.000Z Cypherpunk Technologies to Report Third Quarter 2026 Financial Results on November 16, 2026 https://www.biopharmawatch.com/news/CYH/community-health-systems-exchange-offer BiopharmaWatch en 2026-11-10T00:00:00.000Z Community Health Systems Announces Proposed Exchange Offer and Consent Solicitation https://www.biopharmawatch.com/news/NNOX/nanox-cost-reduction-operational-efficiency BiopharmaWatch en 2026-11-09T22:47:00.000Z Nanox Announces That Board Has Approved Cost Reduction and Operational Efficiency Measures https://www.biopharmawatch.com/news/SNDX/syndax-pharmaceuticals-cfo-inducement-grant BiopharmaWatch en 2026-11-09T22:26:00.000Z Syndax Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/MLAB/mesa-labs-q2-fiscal-2027-results-guidance BiopharmaWatch en 2026-11-09T21:40:00.000Z Mesa Labs Announces Second Quarter Fiscal Year 2027 Results and Issues First Full-Year Guidance